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Introduction: EndoPredict (EP) is an RNA-based multigene test that predicts the likelihood of distant recurrence in
patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) breast
cancer (BC) who are being treated with adjuvant endocrine therapy. Herein we report the prospective-retrospective
clinical validation of EP in the node-positive, chemotherapy-treated, ER+/HER2− BC patients in the GEICAM 9906 trial.
Methods: The patients (N = 1,246) were treated either with six cycles of fluorouracil, epirubicin and cyclophosphamide
(FEC) or with four cycles of FEC followed by eight weekly courses of paclitaxel (FEC-P), as well as with endocrine therapy
if they had hormone receptor–positive disease. The patients were assigned to EP risk categories (low or high) according
to prespecified cutoff levels. The primary endpoint in the clinical validation of EP was distant metastasis-free survival
(MFS). Metastasis rates were estimated using the Kaplan-Meier method, and multivariate analysis was performed using
Cox regression.
Results: The molecular EP score and the combined molecular and clinical EPclin score were successfully determined in
555 ER+/HER2− tumors from the 800 available samples in the GEICAM 9906 trial. On the basis of the EP, 25% of
patients (n = 141) were classified as low risk. MFS was 93% in the low-risk group and 70% in the high-risk group
(absolute risk reduction = 23%, hazard ratio (HR) = 4.8, 95% confidence interval (CI) = 2.5 to 9.5; P < 0.0001).
Multivariate analysis showed that, in this ER+/HER2− cohort, EP results are an independent prognostic parameter after
adjustment for age, grade, lymph node status, tumor size, treatment arm, ER and progesterone receptor (PR) status and
proliferation index (Ki67). Using the predefined EPclin score, 13% of patients (n = 74) were assigned to the low-risk group,
who had excellent outcomes and no distant recurrence events (absolute risk reduction vs high-risk group = 28%;
P < 0.0001). Furthermore, EP was prognostic in premenopausal patients (HR = 6.7, 95% CI = 2.4 to 18.3; P = 0.0002) and
postmenopausal patients (HR = 3.3, 95% CI = 1.3 to 8.5; P = 0.0109). There were no statistically significant differences in
MFS between treatment arms (FEC vs FEC-P) in either the high- or low-risk groups. The interaction test results between
the chemotherapy arm and the EP score were not significant.
Conclusions: EP is an independent prognostic parameter in node-positive, ER+/HER2− BC patients treated with
adjuvant chemotherapy followed by hormone therapy. EP did not predict a greater efficacy of FEC-P compared to
FEC alone.* Correspondence: mmartin@geicam.org
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Several prognostic multigene tests have been developed
for estrogen receptor-positive (ER+) early breast cancer
(BC) patients [1-7]. Large clinical validation studies have
demonstrated that molecular assays are useful for strati-
fying patients into risk categories and helpful in making
clinical treatment decisions in ER+/node-negative BC
patients. Much less is known, however, about the prog-
nostic performance of these tests in patients with axil-
lary lymph node–positive disease. So far, only a few of
these assays have been validated in large node-positive
BC cohorts treated with endocrine or chemoendocrine
treatment. For instance, the 21-gene recurrence score
(RS) was initially established and validated in node-
negative BC patients [1,7,8]. Later, the SWOG-8814
study demonstrated that RS was able to predict distant
metastases in node-positive BC patients [9]. However,
SWOG-8814 and other trials [10] demonstrated that
putative low-risk patients have a considerable, sustained
risk for distant metastases. Therefore, the question
remains whether multigene assays can be used to (1)
identify node-positive BC patients for who can safely be
spared from undergoing chemotherapy and (2) tailor
more intensive or novel drug-based treatment strat-
egies in clinically high-risk cohorts. Additionally, none
of the available tests has yet been validated to predict
taxane efficacy [10-12].
The EndoPredict (EP) test has recently been intro-
duced as an RNA-based multigene test to predict the
likelihood of distant recurrence in ER-positive/HER2-
negative (ER+/HER2−) BC patients treated with adjuvant
endocrine therapy. The test is designed to be used in a
decentralized setting in molecular pathology laboratories
[6,13-15]. Training in the use of EP was noticeably differ-
ent compared to other prognostic tests: node-negative
and node-positive ER+/HER2− BC patients (n = 964)
were included in the multigene algorithm design, and a
combined score of EP, tumor size and nodal status
(EPclin) was defined in the large training cohort. EP was
subsequently validated in two randomized phase III trials
(Austrian Breast and Colorectal Cancer Study Group trials
ABCSG6 and ABCSG8; n > 1,700) that included postmeno-
pausal node-negative and node-positive BC patients treated
with endocrine therapy alone [6]. Subgroup analyses within
the ABCSG validation studies indicated that EP and
EPclin could be used to identify subgroups showing re-
markable differences in 10-year distant recurrence rates in
patients with node-negative and node-positive disease.
Although the ABCSG6 and ABCSG8 studies demon-
strated that EP results enabled the identification of a
subgroup of node-positive BC patients with particu-
larly good clinical outcomes, the performance of EP in
chemotherapy-treated, node-positive patients has not
been evaluated yet.In this study, we validated the EP score in node-positive
ER+/HER2− BC patients in the GEICAM 9906 trial, who
were treated with adjuvant chemotherapy followed by hor-
mone therapy. We also evaluated whether EP results could
predict the efficacy of incorporating weekly paclitaxel into
anthracycline-based regimens.
Methods
Patients and tumor samples
The patients included in this study participated in the
GEICAM 9906 trial, a randomized phase III trial com-
paring two adjuvant chemotherapy regimens after BC
surgery in 1,246 women with lymph node–positive dis-
ease [16,17]. The patients were treated either with six
21-day cycles of 5-fluorouracil, epirubicin and cyclophos-
phamide (FEC; control arm) or with four 21-day cycles of
FEC followed by eight weekly courses of paclitaxel (FEC-P;
experimental arm). Hormone receptor–positive patients
received hormone treatment after chemotherapy. The
median follow-up duration for the whole cohort was
8.7 years. Details of the study design and the patients’
characteristics have been reported previously [16]. The
study was performed in accordance with the Declar-
ation of Helsinki and approved by the ethics commit-
tees at all participating institutions (Additional file 1:
Figure S1) as well as the Spanish Health Authority. It
is registered with the US National Institutes of Health
(ClinicalTrials.gov Identifier: NCT00129922). All patients
provided their written informed consent for therapy
randomization and molecular analyses.
Tumor blocks for the EP validation were collected at
the time of surgery. Formalin-fixed, paraffin-embedded
(FFPE) tumor blocks were available from 800 of the
1,246 patients who participated in the GEICAM 9906
trial. Hematoxylin and eosin–stained sections from each
FFPE tissue block were evaluated by a pathologist at a
GEICAM central laboratory. ER, PR and Ki67 expression
were assessed by immunohistochemistry (IHC) in a cen-
tral laboratory. ER and PR staining were scored accord-
ing to the Allred method as previously described [17,18].
Two 5-μm tissue sections were obtained from each
tumor sample.
RNA extraction and gene expression analysis
Total RNA was extracted from 5-μm whole FFPE tissue
sections using a silica bead–based, fully automated isola-
tion method (VERSANT Tissue Preparation Reagents Kit;
Siemens Healthcare Diagnostics, Tarrytown, NY, USA)
[19-21]. The method includes fully automated deparaffini-
zation, DNase I digestion and an RNA extraction step.
DNA-free total RNA from one FFPE section was ultimately
eluted with 100 μl of elution buffer and stored at −80°C.
To identify ER+/HER2− patients, ESR1 and ERBB2 gene
expression levels were analyzed by qRT-PCR in the FFPE
Table 1 Characteristics of participating breast cancer







Age, yr ER (Allred scoreb)
<50 250 (45%) 0 53 (9.6%)




Premenopausal 300 (54%) 5 28 (5.1%)
Postmenopausal 255 (46%) 6 66 (11.9%)
Nodal status 7 130 (23.4%)
N1 357 (64%) 8 256 (46.1%)
N2 151 (27%) Unknown 3 (0.5%)
N3 47 (9%) PR (Allred scoreb)
T stage 0 104 (18.7%)
1 252 (45%) 3 10 (1.8%)
2 276 (50%) 4 14 (2.5%)
3 27 (5%) 5 42 (7.6%)
Grade 6 48 (8.7%)
1 91 (16%) 7 65 (11.7%)
2 260 (47%) 8 268 (48.3%)
3 157 (28%) Unknown 4 (0.7%)
Unknown 47 (9%) Ki67 (%)
Median (min-max) = 5 (0 to 80)
Treatment arm Low (<14%) 400 (72.1%)
FEC 280 (50.5) High (≥14%) 134 (24.1%)
FEC-P 275 (49.5) Unknown 21 (3.8%)
aER: Estrogen receptor; FEC: Fluorouracil, epirubicin and cyclophosphamide;
FEC-P: Fluorouracil, epirubicin and cyclophosphamide followed by weekly
paclitaxel; HER2: Human epidermal growth factor receptor 2; PR: Progesterone
receptor. bAllred et al. [18]. Patient data were drawn from the GEICAM 9906 trial
(n = 555).
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recently described [6]. A high concordance between quanti-
tative RT-PCR and IHC-based assessments of ER/HER2 sta-
tus has been reported before [21]. The EP assay is based on
the quantification of eight cancer-related genes of interest
(BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1, MGP
and STC2) and three reference genes (CALM2, OAZ1
and RPL37A). This assay was performed as previously
described [6]. In brief, samples were measured in trip-
licate in 384-well plates by quantitative RT-PCR using
an ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems, Foster City, CA, USA) and the
SuperScript III Platinum One-Step qRT-PCR Kit with
ROX (Invitrogen, Karlsruhe, Germany). The thermal
protocol included 30 minutes at 50°C, 20.5 minutes at
8°C and 2 minutes at 95°C, followed by 40 cycles of
15 seconds at 95°C and 30 seconds at 60°C.
The EPclin score, which combines the EP score with two
clinical risk factors (nodal status and tumor size), was cal-
culated as previously described [6]: EPclin score = 0.35∙t +
0.64∙n + 0.28∙s, where t codes the tumor size (1: ≤1 cm,
2: >1 to ≤2 cm, 3: >2 to ≤5 cm and 4: >5 cm), n codes
the nodal status (1: negative, 2: one to three positive
nodes, 3: four to ten positive nodes, and 4: more than
ten positive nodes) and s is the EP score. Both EP and
EPclin scores were used to stratify patients into low-
risk and high-risk groups [6]. Patients with an EP score
<5 (EPclin score <3.3) were classified as being at low
risk for distant recurrence, and patients with an EP
score ≥5 (EPclin score ≥3.3) were categorized as being
at high risk.
Statistical analysis
The primary endpoint of the present study was distant
metastasis-free survival (MFS), defined as the interval
between the date of randomization until the date of dis-
tant metastatic recurrence or death due to disease pro-
gression as the first event. Deaths due to any other causes
were censored. We define distant metastatic recurrence as
excluding ipsilateral breast tumor recurrence, regional in-
vasive recurrence (ipsilateral axilla, internal mammary and
infra- and supraclavicular node metastases), contralateral
BC and all in situ carcinomas. Because these events are
potentially nonlethal, they were also censored. Overall sur-
vival (OS) was the secondary endpoint. All analyses were
conducted according to a prespecified statistical analysis
plan using predefined objectives and cutoff values in ac-
cordance with the prospective-retrospective design out-
lined by Simon et al. [22]. Metastasis rates and OS were
estimated using the Kaplan–Meier method. A logrank
test was used to compare MFS and OS between EP risk
groups and between treatment arms. We used Cox pro-
portional hazards models to calculate hazard ratios (HRs)
and their 95% confidence intervals (95% CIs) for allanalyzed endpoints. Associations and interactions were
assessed by using multivariate Cox proportional haz-
ards models. Two-sided tests were used to determine
P-values, and P-values <0.05 were considered statisti-
cally significant. Unbiased concordance statistics were
estimated for common clinicopathological parameters
(age; nodal status; tumor size; treatment arm; tumor
grade; and ER and PR status and Ki67 index), EP/EPclin
scores and combinations of them using cross-validation
and resampling. We calculated P-values to test whether
combinations of molecular parameters or clinical variables
were significantly associated with distant metastases.Results
The results of our present study are presented in accord-
ance with reporting recommendations for tumor marker
prognostic studies criteria.
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patients from the GEICAM 9906 trial
As mentioned above, patients in the GEICAM 9906
trial were retrospectively analyzed to evaluate the prog-
nostic performance of EP in node-positive, ER+/HER2−,
chemotherapy-treated patients. A total of 566 of the 800
available tumor samples were categorized as ER+/HER2−
by central gene expression assessment and therefore were
considered eligible for EP measurement. EP was success-
fully determined in 555 (98%) of the 566 ER+/HER2−
samples, whereas 11 samples (2%) were excluded from
further analysis for technical reasons (see the CONSORT
diagram in Additional file 2: Figure S2). Table 1 gives
the patient characteristics, the demographic and prog-
nostic features and the 7-year MFS and OS of patients
whose tumor samples had been centrally tested and
were found to be similar to those that had not been
centrally tested (data not shown) [17]. The 555 eligible
patients were assigned to one of two risk categories (low
or high) according to the predefined EP cutoff value [6].
Twenty-five percent (n = 141) of the ER+/HER2− BC
patients were classified as low risk according to EP
score.
The estimated rates of MFS at 10 years were 93% for
the EP score–based low-risk group (9 events in 141 pa-
tients) and 70% for the EP score–based high-risk group
(110 events in 414 patients), with an absolute risk reduc-
tion of 23% (HR = 4.8, 95% CI = 2.5 to 9.6; P < 0.0001)
(Figure 1A). EP score–based risk categorization was also
significantly associated with OS (secondary endpoint) inA  EP
Figure 1 Kaplan-Meier metastasis-free survival curves for ER+/HER2−
indicating estimated high and low risk of metastasis-free survival (MFS
EPclin results indicating estimated high and low risk of MFS. The cutof
the 95% confidence intervals of the hazard ratios. ARR: Absolute risk reductio
epidermal growth factor receptor 2–negative. The MFS in the EP score–
high-risk group. The MFS in the EPclin-based low-risk category was 100%the GEICAM 9906 ER+/HER2− cohort (HR = 3.9, 95%
CI = 2.0 to 7.5; P < 0.0001) (Additional file 3: Figure S3A).
After examining the univariate relationships between the
clinicopathological variables and MFS (Table 2), on the
basis of a multivariate Cox proportional hazards regression
model adjusted for age, grade, nodal status, tumor size,
treatment arm and ER and PR status and Ki67 index, we
assessed whether EP could be used to provide independent
prognostic information in the ER+/HER2− cohort. Nodal
status and EP score remained significant in the multi-
variate model, suggesting that EP score is an independ-
ent predictor of distant metastasis (Table 3). In both
Tables 2 and 3, the first P-value for each variable rep-
resents the level of statistical significance of the overall
effect of each variable on MFS at the univariate and
multivariate levels, respectively. Additionally, unbiased
concordance index (C-index) estimates were calculated
for the different combinations of the same clinicopath-
ological parameters (age, grade, nodal status, tumor
size, treatment arm and ER and PR status and Ki67
index), as well as EP score combined with clinical vari-
ables and EPclin score (see Figure 2), to evaluate their
differential contributions to prognostic classification in
ER+/HER2−, node-positive BC patients (C-index P-
values were <0.05 in all cases; data not shown). The
combination of all of the aforementioned clinicopatho-
logical parameters resulted in a C-index estimate of
0.65. The addition of the EP score to the combination
of the clinicopathological markers resulted in a signifi-
cant improvement in the predictive accuracy (P <B  EPclin 
breast cancers. (A) Curves representing EndoPredict (EP) test results
). The cutoff point was prespecified at 5. (B) Curves representing
f point was prespecified at 3.3. Numbers in parentheses indicate
n estimated at 10 years; ER+/HER2−: Estrogen receptor–positive/human
based low-risk category was 93% vs 70% in the EP score–based
vs 72% in the EPclin score–based high-risk group.
Table 2 Univariate Cox proportional hazards ratios and
95% confidence intervals in univariate analyses for
association between EndoPredict, clinicopathological
variables and metastasis-free survival
Variables HR (95% CIa) P-value
EP 1.207 (1.134 to 1.285) <0.0001
EPclin 1.916 (1.625 to 2.259) <0.0001
Age 0.977 (0.960 to 0.993) 0.0065
Tumor size 0.0159b
≤1 Reference value
>1 to ≤2 cm 1.038 (0.457 to 2.357) 0.9290
>2 to ≤5 cm 1.919 (0.884 to 4.168) 0.0994
>5 cm 2.102 (0.762 to 5.798) 0.1511
Number of positive nodes <0.0001b
1 to 3 Reference value
4 to 10 1.631 (1.085 to 2.451) 0.0187
>10 4.911 (3.022 to 7.979) <0.0001
Grade 0.0233b
G1 Reference value
G2 2.263 (1.157 to 4.428) 0.0171
G3 2.883 (1.446 to 5.746) 0.0026
Unknown 1.844 (0.749 to 4.538) 0.1829
Treatment arm 0.6067b
FEC Reference value
FEC-P 0.910 (0.635 to 1.304)
ER (Allred scorec) 0.950 (0.886 to 1.019) 0.1505
PR (Allred scorec) 0.923 (0.874 to 0.974) 0.0033
Ki67 (quantitative) 1.017 (1.004 to 1.030) 0.0080
aEP: EndoPredict; EPclin: Combined molecular and clinical score; CI: Confidence
interval; ER: Estrogen receptor; HR: Hazard ratio; MFS: Metastasis-free survival; PR:
Progesterone receptor. Number of patients included in the analyses is 555. bP-value
of the variable’s overall effect on MFS. cAllred et al. [18].
Table 3 Multivariate Cox proportional hazards ratios and
95% confidence intervals for the association between
EndoPredict, selected clinicopathological variables and
metastasis-free survival
Variables HR (95% CIa) P-value
EP 1.126 (1.041 to 1.219) 0.0031
Number Positive Nodes <0.0001b
1 to 3 Reference value
4 to 10 1.420 (0.932 to 2.166) 0.1030
>10 3.605 (2.102 to 6.185) <0.0001
Age 0.983 (0.966 to 1.001) 0.0628
Tumor size 0.6631b
≤1 cm Reference value
>1 to ≤2 cm 0.789 (0.343 to 1.816) 0.5774
>2 to ≤5 cm 1.042 (0.466 to 2.331) 0.9196
>5 cm 0.880 (0.301 to 2.577) 0.8159
Treatment arm 0.9331b
FEC Reference value
FEC-P 1.016 (0.697 to 1.482)
Grade 0.4650b
G1 Reference value
G2 1.662 (0.830 to 3.329) 0.1519
G3 1.589 (0.747 to 3.377) 0.2290
Unknown 1.198 (0.470 to 3.052) 0.7051
ER (Allred scorec) 0.980 (0.903 to 1.063) 0.6207
PR (Allred scorec) 0.965 (0.902 to 1.032) 0.2947
Ki67 quantitative 1.001 (0.986 to 1.016) 0.8982
aCI: Confidence interval; EP: EndoPredict; EPclin: Combined molecular and
clinical score; ER: Estrogen receptor; HR: Hazard ratio; MFS: Metastasis-free sur-
vival; PR: Progesterone receptor. bP-value of the variable’s overall effect on
MFS. cAllred et al. [18]. Multivariate analyses included 534 patients and
116 events.
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http://breast-cancer-research.com/content/16/2/R380.0018) and a C-index estimate of 0.67 (Figure 2). The
EPclin score had the highest C-index estimate (0.70) in
comparison to all analyzed combination strategies.
EPclin was also used to dichotomize patients into
low- and high-risk categories according to the thresh-
old established for the EP test. EPclin score–based risk
stratification was significantly associated with the dis-
tant metastasis rate in the GEICAM 9906 ER+/HER2−
cohort. The estimated rates of MFS at 10 years were
100% for the EPclin-low risk group (0 events in 74 pa-
tients) and 72% for the EPclin high-risk group (119
events in 481 patients), with an absolute risk reduction
of 28% (P < 0.0001) (Figure 1B). Interestingly, on the
basis of EPclin test results, we identified a low-risk
group (74 (13%) of 555 patients), which had no meta-
static events and an OS rate of 99% (Additional file 3:
Figure S3B).Prognostic performance in pre- and postmenopausal
breast cancer patients
The investigators in the GEICAM 9906 trial enrolled
post- and premenopausal BC patients, allowing for sub-
group analysis based on menopausal status. Of the 555
ER+/HER2− BC patients, 300 were premenopausal (54%)
and 255 were postmenopausal (46%). In the subgroup
analyses, 73 premenopausal patients (24.3%) and 68
postmenopausal patients (26.7%) were classified as be-
ing at low risk based on the EP test results. The sub-
group analyses based on menopausal status suggested
that EP is prognostic in ER+/HER2− BC patients in the
premenopausal patients (HR = 6.7, 95% CI = 2.4 to
18.3; P < 0.0001) and postmenopausal patients (HR =
3.3, 95% CI = 1.3 to 8.5; P = 0.0069) (Figure 3A). The
EPclin test results also generated a significant risk pro-
file in premenopausal patients (P = 0.0006) and post-











0.54 0.56 0.58 0.6 0.62 0.64 0.66 0.68 0.7 0.72
ER, PR, Ki67
ER, PR, Ki67 + Tumor Size
ER, PR, Ki67 + Tumor Size + Nodal Status
Clinico-pathological parameters
Clinico-pathological parameters + EP
EPclin
c-index
Figure 2 C-index plot for clinicopathological parameters and EndoPredict test results between breast cancer patients with ER+/HER2− tumors.
C-index estimates for different groupings of prognostic parameters are shown: ER + PR + Ki67, ER + PR + Ki67 + tumor size, ER + PR + Ki67 +
tumor size + nodal status, all clinicopathological parameters (nodal status, tumor size, grade, treatment arm, and ER and PR status and Ki67
index), all clinicopathological parameters + EndoPredict (EP) score, and combined molecular and clinical EPclin. ER: Estrogen receptor;
PR: Progesterone receptor. P-values indicate whether additional molecular parameters add significant prognostic information to
clinical variables.
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The GEICAM 9906 trial was conducted to compare
the effect of adding weekly paclitaxel to conventional
anthracycline-based (FEC) chemotherapy. Therefore, the
treatment and outcome information produced in the ran-
domized trial allowed us to test whether EP is predictive
of whether treatment with weekly paclitaxel is greater effi-
cacy than FEC. Adding weekly paclitaxel treatment did
not significantly reduce the risk of relapse in the 555
ER+/HER2− BC patients analyzed (HR = 1.1, 95% CI = 0.8
to 1.6; P = 0.6067) (Additional file 4: Figure S4). MFS
differences between treatment arms also failed to reach
statistical significance in both the EP high- and low-risk
groups (Figure 4). The interaction between the EP score
and treatment arm was also nonsignificant (P = 0.71). Add-
itionally, we found no significant treatment effects for OS
(data not shown) or EPclin (Additional file 5: Figure S5).
However, the 100% MFS of EPclin low-risk patients in the
FEC arm suggests that this group might not benefit from
the addition of paclitaxel.
Discussion
The EP test has recently been validated in two large
phase III trials (ABCSG6 and ABCSG8) that included
postmenopausal ER+/HER2− BC patients treated with
endocrine therapy alone. The ABCSG trials demonstrated
that EP adds significant prognostic information to all
commonly used clinicopathological parameters (including
ER and Ki67) and clinical guidelines [6,13]. In line with
the ABCSG6 and ABCSG8 clinical validation studies, we
conducted a third clinical validation for the EP test by
using archived tissue material according to the prospect-
ive-retrospective design described by Simon et al. [22]. Inour present study, we analyzed EP-based data retrospect-
ively in a large FFPE sample set derived from the phase III
GEICAM 9906 trial on the basis of prospectively acquired
clinical data and prespecified study objectives and labora-
tory assays.
To the best of our knowledge, this study is the first to
show that EP is an independent prognostic parameter for
both MFS and OS in node-positive, ER+/HER2− BC patients
treated with adjuvant chemotherapy followed by hormone
therapy. Also, in this cohort selected by ER+/HER2− status,
EP test results add prognostic information to other common
clinicopathological variables in this cohort. EP test results
provide important information regarding the residual
risk of recurrence after a modern anthracycline plus
taxane chemotherapy regimen.
The results we report further suggest that EP better
captures the tumor-derived intrinsic factors that lead to
distant metastasis in node-positive, ER+/HER2− disease
compared with some of the clinicopathological markers
traditionally used to make treatment decisions (age, grade,
nodal status, tumor size, treatment arm, and ER and PR
status and Ki67 index).
What are the clinical implications of our results? The
EP-/EPclin-based risk classification identifies a subgroup
with a particularly low rate of distant metastatic events
in a node-positive, high-risk cohort treated with anthra-
cycline with or without a taxane-containing chemother-
apy, followed by 5 years of endocrine therapy. In the
face of 100% estimated distant MFS in the EPclin-based
low-risk group, one might speculate that this patient
group does not need an extension of endocrine therapy
beyond 5 years. This finding is clinically relevant because
the results of several clinical trials suggest that the
A EP premenopausal EP postmenopausal
EPclin premenopausal EPclin postmenopausalB
Figure 3 Kaplan-Meier metastasis-free survival curves for ER+/HER2− breast cancers. (A) Curves representing EndoPredict (EP) test results
indicating estimated high and low risk of metastasis-free survival (MFS). The cutoff point for EP score–based risk stratification was prespecified
at 5. For the premenopausal patients, MFS in the EP score–based low-risk category was 93% vs 67% in the EP score–based high-risk group.
For the postmenopausal patients, MFS in the EP score–based low-risk category was 92% vs 74% in the EP score–based high-risk group. (B) Curves
representing results based on the combined molecular and clinical EPclin indicating estimated high and low risk of MFS. The cutoff point for EPclin
score–based risk stratification was prespecified at 3.3. In the EPclin premenopausal patients, MFS in the EPclin score–based low-risk group was 100% vs
70% in the EPclin score–based high-risk category. In the postmenopausal patients, MFS in the EPclin score–based low-risk category was 100% vs 76%
in the EPclin score–based high-risk group. The samples included 300 premenopausal patients and 255 postmenopausal patients. Numbers in parentheses
indicate the 95% confidence intervals of the hazard ratios. ARR: Absolute risk reduction estimated at 10 years.
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in patients with ER+ BC in order to prevent late metas-
tasis [23-28]. Additionally, EP-based low-risk patients
can be sufficiently treated with standard chemotherapy.
On the basis of our results, one might even speculate
that the EP-based low-risk, node-positive ER+/HER2−
patients treated with endocrine therapy might not derive
any benefit from chemotherapy.
Several prognostic tests have been validated for BC pa-
tients in the past decade. The Oncotype DX Breast Can-
cer Assay (Genomic Health, Redwood City, CA, USA)
and the MammaPrint diagnostic test (Agendia, Irvine,CA, USA) were the first commercially available gene ex-
pression tests to predict the risk of recurrence in early-
stage BC [1-3]. Whereas researchers in decision impact
studies have demonstrated that both tests reduce health-
care costs and spare patients from unnecessary chemother-
apy [29-31]. Oncotype DX has a higher level of supporting
evidence than MammaPrint on the basis of large prospect-
ive-retrospective clinical validation studies. However, a re-
cent biomarker substudy of the Arimidex, Tamoxifen
Alone or in Combination trial (ATAC; ClinicalTrials.
gov Identifier: NCT00849030) suggested that IHC4 pro-
vides prognostic information similar to that garnered from
EP (low risk group) EP (high risk group)B A
Figure 4 Kaplan-Meier metastasis-free survival curves for ER+/HER2- breast cancer. Comparison of treatment arms (FEC vs. FEC-P) in (A)
the EP low-risk group (n = 141) and (B) the EP high-risk group (n = 414). The cutoff point for EP was prespecified at 5. Numbers in parentheses
indicate the 95% confidence intervals of the hazard ratios. FEC: fluorouracil, epirubicin and cyclophosphamide; FEC+P: fluorouracil, epirubicin and
cyclophosphamide followed by eight weekly courses of paclitaxel.
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Clarient InsightDx Mammostrat test (Clarient Diagnostic
Services, Aliso Viejo, CA, USA)—expanded immunohisto-
chemical tests—can be used to determine the expression
levels of diverse protein panels [33]. Although both tests
are valuable as predictors for risk of recurrence, further
statistical validation is still needed to ascertain whether
these IHC tests can be standardized for everyday clinical
use [34]. EP test results, together with other second-
generation multigene tests (Predictor Analysis of Micro-
array 50-gene test (the PAM50 Breast Cancer Intrinsic
Classifier) and Breast Cancer Index assay), have recently
been introduced. In contrast to first-generation multigene
algorithms and IHC4, these tests can also be used to pre-
dict late metastases [35-37]. Additionally, the PAM50 and
EP tests can be carried out in a decentralized setting [15].
Most of the prognostic tests mentioned herein were ini-
tially developed to improve decision-making in the clinical
management of node-negative BC patients [1,4,5,7]. Al-
though some prognostic tests have been evaluated in het-
erogeneous patient populations, including patients with
node-positive tumors, data regarding node-positive dis-
ease are scarce. Oncotype DX was the first prognostic
multigene test validated in a large clinical trial of node-
positive patients, the SWOG-8814 study, which dem-
onstrated that Oncotype DX was effective in identifying
subgroups with fair prognoses, although the likelihood of
distant relapse still exceeded 30% in the low-risk group [9].
Our present study contributes to the literature by providing
additional evidence suggesting that multigene tests can be
used in patients with node-positive disease. Furthermore,
in contrast to the Oncotype DX–derived data mentioned
above, our EP-based results strongly suggest that the EP-
based low-risk group has a considerably low residual risk ofdistant recurrence (<10%) after standard chemotherapy. In
contrast, high-risk patients have a high probability of exhi-
biting residual disease after conventional chemotherapy
and should be considered for a tailored extension or in-
tensification of adjuvant treatment, as well as for registra-
tion in clinical trials testing novel treatment strategies.
As a secondary aim in this study, we analyzed whether
EP could be used to identify patients who might benefit
from the addition of weekly paclitaxel to anthracycline-
based chemotherapy treatment. Taxanes, although they
are more toxic than conventional anthracycline-based reg-
imens, are one of the most active cytotoxic agents and are
widely used in standard chemotherapy. However, the ab-
solute benefit of taxane-based treatment is small (3% to
7% absolute OS benefit within 5 years after treatment)
[16,38-41] and needs to be balanced against serious side
effects. Thus, there is an urgent need for novel predictors
regarding which subgroups of patients stand to benefit
substantially from treatment with taxanes. Of the several
molecular markers analyzed as predictors of taxane effi-
cacy [42-44], none of the markers or prognostic multigene
assays have indicated that taxane benefits are maintained
across relevant patient subgroups [10,11]. Similarly, our
present results show that EP test results were not predict-
ive of the efficacy of taxanes, because patients receiving
weekly paclitaxel in addition to anthracycline-based
chemotherapy did not experience any significant bene-
fit. However, these results should be interpreted in the
context of the main limitation of our study: a small sample
size. Sample size is especially important in the validation of
a predictive marker in patients with ER+/HER2− tumors,
which are generally less chemoresponsive [45] and less ef-
fective in taxane-based treatment [16] compared with pa-
tients with other tumors.
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sponse are poorly understood and still a matter of de-
bate. Recently, we reported that a low proliferation score
(11 cell-cycle genes) was predictive of weekly paclitaxel
efficacy in the GEICAM 9906 trial [11]. Although the
question whether this association also exists in patients
with ER+/HER2− tumors was not examined, the associ-
ation might be relevant in this context because prolifera-
tion is one of the strongest variables in calculating the
EP test score, as well as in other available prognostic
multigene tests. In contrast, the proliferation marker Ki67
was identified as predictive in luminal tumors treated with
chemotherapy that included docetaxel [44], and patients
with luminal B tumors benefited from taxane-based treat-
ment [44,46]. The aforementioned conflicting results sug-
gest that there are still a number of key processes in need
of further study to elucidate the interaction between
markers, taxane agents (paclitaxel and docetaxel), doses
applied, administration schedules and treatment strategy
duration.
Conclusions
The results of our study show that EP provides additional
prognostic information in the GEICAM 9906 trial ER
+/HER2− cohort. This is the third clinical validation study
of the EP score based on a prospective-retrospective
design. It supports the high clinical evidence level of EP
(level Ib according to Simon et al. [22]). Additionally, our
study findings suggest that EP is prognostic in pre- and
postmenopausal BC patients.
In line with other prognostic multigene assays, EP
failed to predict the benefit of adding weekly paclitaxel
to anthracycline-based chemotherapy in the GEICAM
9906 trial. However, EP might help to identify patients
who are not being treated sufficiently with a standard
taxane and/or anthracycline-based cytotoxic chemother-
apy regimen and who might be eligible for treatment
strategies with novel drugs.
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